Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements.

Publication date: April 2016
Source:Critical Reviews in Oncology/Hematology, Volume 100
Author(s): Vitaliana De Sanctis, Paolo Bossi, Giuseppe Sanguineti, Fabio Trippa, Daris Ferrari, Almalina Bacigalupo, Carla Ida Ripamonti, Michela Buglione, Stefano Pergolizzi, Johannes A. Langendjik, Barbara Murphy, Judith Raber-Durlacher, Elvio G. Russi, Rajesh V. Lalla
BackgroundOral mucositis (OM) due to radiotherapy and systemic therapies in head and neck cancer treatment represents a major problem causing a wide spectrum of clinical signs and symptoms. This adverse event may reduce quality of life, resulting from debilitating oral pain, bleeding, dysphagia, infections, impairment of food intake, high rate of hospitalization and may interfere with the delivery of programmed treatment plans, ultimately jeopardizing patient outcome. Globally, there is a lack of evidence on effective measures for the prevention and treatment of OM, and only scant uniform conclusions and recommendations can be derived from the existing literature and guidelines. A multidisciplinary team of Italian head and neck cancer experts met in Milan 17–18 February 2013 with the aim of reaching consensus on prophylaxis and management of mucositis. The results of the literature review and the statements that achieved consensus are reported and discussed in this paper.Material and methodsThe Delphi Appropriateness Method was used as a structured communication method for achieving consensus. Subsequently, external expert reviewers evaluated the conclusions carefully according to their area of expertise.ResultsThis paper presents 13 clusters of statements on prophylaxis and treatment of mucositis that achieved consensus.ConclusionsOM represents a very stressfull situation for head and neck cancer patients submitted to chemo-radiation or exclusive radiation treatment. A multidisciplinary approach is mandatory, but there is still no gold-standard protocol that is prominently better than others.



from Cancer via ola Kala on Inoreader http://ift.tt/1UyQnoD
via IFTTT